190 related articles for article (PubMed ID: 31945264)
21. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
Ayyar BV; Aoki KR; Atassi MZ
Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
[TBL] [Abstract][Full Text] [Related]
22. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.
Kroken AR; Karalewitz AP; Fu Z; Kim JJ; Barbieri JT
J Biol Chem; 2011 Jul; 286(30):26828-37. PubMed ID: 21632541
[TBL] [Abstract][Full Text] [Related]
23. Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.
James NG; Malik S; Sanstrum BJ; Rhéaume C; Broide RS; Jameson DM; Brideau-Andersen A; Jacky BS
Sci Rep; 2021 Apr; 11(1):7832. PubMed ID: 33837264
[TBL] [Abstract][Full Text] [Related]
24. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.
Rummel A
Curr Top Microbiol Immunol; 2013; 364():61-90. PubMed ID: 23239349
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC.
Zhang S; Berntsson RP; Tepp WH; Tao L; Johnson EA; Stenmark P; Dong M
Nat Commun; 2017 Nov; 8(1):1637. PubMed ID: 29158482
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of cell surface receptor recognition by botulinum neurotoxin B.
Chai Q; Arndt JW; Dong M; Tepp WH; Johnson EA; Chapman ER; Stevens RC
Nature; 2006 Dec; 444(7122):1096-100. PubMed ID: 17167418
[TBL] [Abstract][Full Text] [Related]
27. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
Yin L; Masuyer G; Zhang S; Zhang J; Miyashita SI; Burgin D; Lovelock L; Coker SF; Fu TM; Stenmark P; Dong M
PLoS Biol; 2020 Mar; 18(3):e3000618. PubMed ID: 32182233
[TBL] [Abstract][Full Text] [Related]
29. Unique ganglioside binding by botulinum neurotoxins C and D-SA.
Kroken AR; Karalewitz AP; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
FEBS J; 2011 Dec; 278(23):4486-96. PubMed ID: 21554541
[TBL] [Abstract][Full Text] [Related]
30. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
31. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Rummel A; Häfner K; Mahrhold S; Darashchonak N; Holt M; Jahn R; Beermann S; Karnath T; Bigalke H; Binz T
J Neurochem; 2009 Sep; 110(6):1942-54. PubMed ID: 19650874
[TBL] [Abstract][Full Text] [Related]
32. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.
Rummel A; Eichner T; Weil T; Karnath T; Gutcaits A; Mahrhold S; Sandhoff K; Proia RL; Acharya KR; Bigalke H; Binz T
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):359-64. PubMed ID: 17185412
[TBL] [Abstract][Full Text] [Related]
33. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
Kroken AR; Blum FC; Zuverink M; Barbieri JT
Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365
[TBL] [Abstract][Full Text] [Related]
34. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other.
Atassi MZ; Taruishi M; Naqvi M; Steward LE; Aoki KR
Protein J; 2014 Jun; 33(3):278-88. PubMed ID: 24740609
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.
Leka O; Wu Y; Li X; Kammerer RA
J Biol Chem; 2021; 296():100684. PubMed ID: 33891946
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction.
Stenmark P; Dupuy J; Imamura A; Kiso M; Stevens RC
PLoS Pathog; 2008 Aug; 4(8):e1000129. PubMed ID: 18704164
[TBL] [Abstract][Full Text] [Related]
37. High-resolution crystal structures of the botulinum neurotoxin binding domains from subtypes A5 and A6.
Davies JR; Britton A; Liu SM; Acharya KR
FEBS Open Bio; 2020 Aug; 10(8):1474-1481. PubMed ID: 32654405
[TBL] [Abstract][Full Text] [Related]
38. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
[TBL] [Abstract][Full Text] [Related]
39. Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D.
Zhang Y; Gardberg AS; Edwards TE; Sankaran B; Robinson H; Varnum SM; Buchko GW
Biochimie; 2013 Jul; 95(7):1379-85. PubMed ID: 23523511
[TBL] [Abstract][Full Text] [Related]
40. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
Jin R; Rummel A; Binz T; Brunger AT
Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
